AccelStor Smashes Performance Barriers with NeoSapphire All-Flash Array
AccelStor, the software-defined all-flash array provider, will be demonstrating its NeoSapphire H710 all-flash array at SC17 (SuperComputing 2017) for high performance computing solutions. The advantage of the NeoSapphire series and the advanced AccelStor FlexiRemap® technology is making HPC applications simpler and more efficient with its powerful performance and impressive scalability. The latest H710 will be showcased during SC17, at booth #1972, at the Colorado Convention Center, Denver, USA from November 13-17, 2017.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171109005019/en/
The NeoSapphire H710 packs over 600K sustained IOPS for 4KB random writes, ideal for HPC applications. (Photo: Business Wire)
SC17 is the premier international conference showcasing the many aspects of high performance computing, networking, storage and analysis leading to advances in scientific discovery, research, education and commerce. HPC (High-Performance Computing) specifically refers to running advanced applications efficiently and reliably. The high performance and true high availability design of the NeoSapphire H710 all-flash array makes it the perfect solution for HPC systems. Furthermore, the exclusive FlexiRemap® technology enables the all-flash array to meet the most complicated of data-access demands, making it best-suited for HPC applications.
AccelStor Vice President, David Kao, said “We are thrilled about our latest NeoSapphire H710. It’s designed to unleash the true performance of flash technology, and remove bottlenecks, enabling a seamless system experience, easy installation, computing efficiency, scalability and faster time to results. The most common demand and need for HPC comes from scientific researchers, engineers and academic institutions. For our customers who desire extreme-scale computing, reliability and high availability, they will definitely benefit from the NeoSapphire H710.”
Sustained High IOPS Performance
Real-world HPC applications need more than high, “peak” performance. As flash appliances often provide high-speed, shared storage services to multiple front-end compute nodes, high sustained IOPS is the real driver in flash storage performance for I/O-intensive HPC applications. Thanks to the award-winning FlexiRemap® technology, and its patented data handling algorithm, is specifically designed just for flash memory and it can outperform competitors when dealing with the most complicated 4KB random write data access, even under dramatically heavy workloads. The NeoSapphire H710 packs over 600K sustained IOPS for 4KB random writes in a single 4U rack over standard 10GbE or 16G Fibre Channel LC SFP+ network interfaces.
Low Operating Expenses and Rich Data Service Tools
AccelStor’s high availability (HA) flash storage solution address the challenges operators face by enabling them to improve the reliability and reduce high OPEX (Operating Expenses). The NeoSapphire High Availability AFA delivers world-class reliability. Based on a shared-nothing architecture and redundant hardware design, this model uses enterprise SSDs with a long lifespan suitable for write-intensive workload applications. The NeoSapphire product range features a rich suite of software features and performance-boosting technology, including Free Clone, thin provisioning, thick provisioning and FlexiDedupe™ pre-bundled with each system. In order to provide the best redundancy and data protection, the H710 also comes with Remote Replication, Redirect-on-Write Snapshot, Snapshot Backup/Recovery and Group Snapshot for database usage as standard.
Scalability and High Availability
AccelStor helps clients achieve a competitive business advantage by delivering sustained performance of 600K IOPS at 4KB random write, reliability and scalability. Customers frequently experience an imbalance of capacity and performance as business grows, enterprises will feel the pain of compromises, caused by unpredictable costs of adding capacity and falling performance. The NeoSapphire H710 supports on-demand scale-up from a basic 27TB in 4U rack to a max. 221TB in 12U rack. Its shared-nothing architecture with FlexiRemap® technology also ensures no single point of failure, no data loss and essentially no downtime.
Download the NeoSapphire
H710 Product Sheet
Learn more about the NeoSapphire all-flash array high-availability series
Learn more about FlexiRemap® Technology
Follow AccelStor on Twitter: @AccelStor
Follow AccelStor on Linkedin
About AccelStor, Inc.
AccelStor is accelerating the paradigm shift from conventional disk arrays to modern all-flash storage. AccelStor's NeoSapphire all-flash arrays, powered by FlexiRemap software technology, deliver sustained high IOPS for business-critical applications. With streamlined storage management, multi-protocol support, and front-access, hot-swappable solid-state drives, the NeoSapphire series promises to resolve performance bottlenecks for I/O-intensive applications like artificial intelligence, IoT, data center, virtualization, high-performance computing, database, media processing, fintech and gaming. For more information about AccelStor and NeoSapphire, please visit www.accelstor.com.
AccelStor, FlexiRemap and NeoSapphire are trademarks or registered trademarks of AccelStor, Inc. in the United States of America and/or other countries.
* IOPS test results mentioned in this press release are generated by AccelStor and may vary in different test environments.
Clara Lee, +886 2 77467616 ext. 2561
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 15:00 | Tiedote
Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior
NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 15:00 | Tiedote
NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip
Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 14:27 | Tiedote
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea
Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00 | Tiedote
Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba
ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11 | Tiedote
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme